Abstract: The disclosure provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The disclosure also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food. The disclosure further provides a method of using the nutritional supplement for treating patients with heart failure.

Abstract: The present invention provides a nutritional composition for improving a patient with heart failure; the nutritional composition is consisting of therapeutically effective high amounts of leucine and histidine. The present invention also provides the nutritional supplement comprising the nutritional composition, which may be a beverage product, a dietary supplement or food. The present invention further provides a method of using the nutritional supplement for treating patients with heart failure.

Abstract: A method for diagnosing heart failure in a subject is provided. The method includes steps of measuring a biological sample of the subject to obtain an amount of at least one biomarker selected from the group consisting of xanthine, spermidine, propionylcarnitine, butyrylcarnitine and P-cresyl sulfate; and comparing the amount of the at least one biomarker to a reference. Moreover, the present invention relates to a method for staging heart failure or evaluating a prognosis of heart failure in a subject.

Abstract: This invention features a method for treating inflammatory injury to the cardiovascular system caused by oxidized low density lipoprotein. The method includes administering to a subject in need an effective amount of a composition containing salvianolic acid B.

Abstract: The present invention relates to a nutraceutical composition that contains lithospermic acid enriched from an extract of T. samentosa, or contains lithospermic acid and salvianolic acid B co-enriched from an extract of S. miltiorrhiza.

Abstract: The present invention provides a pharmaceutical kit useful for treating cancer cells in a mammal. Using this kit, the cancer cells are first sensitized by administering to the mammal an agent which comprises an effective amount of a HMG-CoA reductase inhibitor. The sensitized cancer cells are then treated with an anti-cancer agent which reduces the survival or growth of the cancer cells.

Abstract: A method for identifying and isolating the active fractions in Cordyceps sinensis. It covers a findings of the structure of an active compound that is present in the active fraction, an isolation method that can be used to extract the active fractions and a specific active compound, and the use of "H1-A", one specific active compound that is present in the active fractions thus isolated, to ameliorate the clinical symptoms and renal lesions in laboratory mice with induced IgA nephropathy (Berger's disease). This work has important pharmacological implications for the suppression of activated mesangial cells and IgA nephropathy in humans.

Abstract: The present invention provides a composition for evaluating the performance of reverse phase high performance liquid chromatographic columns, especially in the aspect of separating a mixture having stereo- and positional isomers, which comprises oxygenated triterpenoids obtained from the cultured mycelia of Ganoderma lucidum (Fr.) Karat.